Huntleigh Advisors, Inc. Olema Pharmaceuticals, Inc. Transaction History
Huntleigh Advisors, Inc.
- $592 Billion
- Q4 2025
A detailed history of Huntleigh Advisors, Inc. transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Huntleigh Advisors, Inc. holds 20,130 shares of OLMA stock, worth $174,929. This represents 0.08% of its overall portfolio holdings.
Number of Shares
20,130Holding current value
$174,929% of portfolio
0.08%Shares
1 transactions
Others Institutions Holding OLMA
# of Institutions
138Shares Held
64.6MCall Options Held
379KPut Options Held
13K-
Bain Capital Life Sciences Investors, LLC Boston, MA6.84MShares$59.5 Million21.2% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.79MShares$59 Million2.11% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$46 Million2.76% of portfolio
-
Black Rock Inc. New York, NY4MShares$34.8 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X03.59MShares$31.2 Million0.02% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $351M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...